dc.creator | Melo González, Felipe | |
dc.creator | Méndez, Constanza | |
dc.creator | Peñaloza, H.F. | |
dc.creator | Schultz, B.M. | |
dc.creator | Piña Iturbe, A. | |
dc.creator | Ríos, M. | |
dc.creator | Moreno Tapia, D. | |
dc.creator | Pereira Sánchez, P. | |
dc.creator | Leighton, D. | |
dc.creator | Orellana, C. | |
dc.creator | Covarrubias, C. | |
dc.creator | Gálvez, N.M.S. | |
dc.creator | Soto, J.A. | |
dc.creator | Duarte, L.F. | |
dc.creator | Rivera Pérez, D. | |
dc.creator | Vázquez, Y. | |
dc.creator | Cabrera, A. | |
dc.creator | Bustos, S. | |
dc.creator | Iturriaga, C. | |
dc.creator | Urzua, M. | |
dc.creator | Navarrete, M.S. | |
dc.creator | Rojas, Á. | |
dc.creator | Fasce, R. | |
dc.creator | Fernández, J. | |
dc.creator | Mora, J. | |
dc.creator | Ramírez, E. | |
dc.creator | Gaete Argel, A. | |
dc.creator | Acevedo, M. | |
dc.creator | Valiente Echeverría, F. | |
dc.creator | Soto Rifo, R. | |
dc.creator | Weiskopf, D. | |
dc.creator | Grifoni, A. | |
dc.creator | Sette, A. | |
dc.creator | Zeng, G. | |
dc.creator | Meng, W. | |
dc.creator | González Aramundiz, J.V. | |
dc.creator | González, P.A. | |
dc.creator | Abarca, K. | |
dc.creator | Bueno, S.M. | |
dc.creator | Kalergis, A.M. | |
dc.date.accessioned | 2023-07-10T13:33:13Z | |
dc.date.accessioned | 2023-09-14T21:27:40Z | |
dc.date.available | 2023-07-10T13:33:13Z | |
dc.date.available | 2023-09-14T21:27:40Z | |
dc.date.created | 2023-07-10T13:33:13Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1101/2022.08.22.22279080 | |
dc.identifier | http://doi.org/10.1101/2022.08.22.22279080 | |
dc.identifier | https://repositorio.uc.cl/handle/11534/74133 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8798479 | |
dc.description.abstract | The SARS-CoV-2 Omicron variant has challenged the control of the COVID-19 pandemic even in highly vaccinated countries. While a second booster of mRNA vaccines improved the immunity against SARS-CoV-2, the humoral and cellular responses induced by a second booster of an inactivated SARS-CoV-2 vaccine have not been studied. In the context of a phase 3 clinical study, we report that a second booster of CoronaVac® increased the neutralizing response against the ancestral virus yet showed poor neutralization against the Omicron variant. Additionally, isolated PBMCs displayed equivalent activation of specific CD4+ T cells and IFN-γ production when stimulated with a mega-pool of peptides derived from the spike protein of the ancestral virus or the Omicron variant. In conclusion, a second booster dose of CoronaVac® does not improve the neutralizing response against the Omicron variant compared with the first booster dose, yet it helps maintaining a robust spike-specific CD4+ T cell response. | |
dc.language | en | |
dc.rights | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.rights | acceso abierto | |
dc.title | Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults | |
dc.type | preprint | |